BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, November 12, 2025
Home » Topics » Wearable, BioWorld MedTech

Wearable, BioWorld MedTech
Wearable, BioWorld MedTech RSS Feed RSS

3-23-Ava-Bracelet-App.png

Fertility wearable to double as COVID-19 temp monitor, as need for population data intensifies

March 23, 2020
By Stacy Lawrence
Zurich-based startup Ava Science Inc. recently issued a public call for partners and funding to further research the potential usefulness of its fertility wearable, known as Ava Bracelet, during the COVID-19 pandemic.
Read More
3-3-element-science-jewel.png

Element Science raises $145.6M series C round to back hospital-to-home, cardiac wearable

March 3, 2020
By Stacy Lawrence
San Francisco-based startup Element Science Inc. has raised a massive financing in support of the first product that is part of its next-generation digital wearable platform. The $145.6 million series C financing is slated to support the company through clinical trial completion and commercial launch of its Jewel Patch Wearable Cardioverter Defibrillator.
Read More
Thumbs up

Irish startup Atlantic goes OTC in the U.S. with wearable treatment for urinary incontinence

Feb. 10, 2020
By Stacy Lawrence
The FDA has granted over-the-counter (OTC) clearance to the first noninvasive wearable to treat stress urinary incontinence. The device, known as Innovo, uses electrical stimulation to strengthen pelvic floor muscles and is integrated into fitted shorts. It was already available by physician prescription in the U.S. since an FDA clearance in early 2019.
Read More
1-29-verily-study-watch.png

Verily gets second Study Watch FDA clearance as it digs into Irhythm AF collaboration

Jan. 29, 2020
By Stacy Lawrence
Diabetes is the first med-tech sphere that is coalescing for Verily Life Sciences LLC, but cardiology could be next. The South San Francisco-based business that’s part of Google parent Alphabet Inc. has received a second FDA clearance for its Verily Study Watch as an irregular pulse monitor. After a 2017 debut, it was first cleared by the agency about a year ago for use to take an on-demand electrocardiogram (ECG).
Read More
1-6-withings-scanwatch.png

Withings to launch AF, sleep apnea detecting smartwatch in Q2, pending regulatory nods

Jan. 6, 2020
By Stacy Lawrence
Issy-les-Moulineaux, France-based Withings SA said it’s planning to launch its latest product in the U.S. and Europe during the second quarter, the Scanwatch. It is expected to be the first smartwatch to offer both atrial fibrillation (AF) and sleep apnea detection; a CE mark and FDA clearance are both pending. Cardiac arrhythmia and sleep apnea are associated with one another and can be precursors to more serious health problems such as heart attack or stroke.
Read More
Blue heart and data grid

Company designs glove to replace echocardiography device

Dec. 31, 2019
By Sergio Held
BOGOTA, Colombia – A startup in Mexico has developed an intelligent glove to diagnose cardiac diseases in seconds just by touching a patient’s chest. The invention could become available on the market by the end of 2020, when Soluciones Kenko, from Jalisco, Mexico, expects to hit the Mexican market with a futuristic solution for the health care sector.
Read More
Kidney illustration

Researchers develop artificial kidney capable of purifying blood to create its own ‘urine’

Dec. 24, 2019
By Stacy Lawrence
Roseville, Calif.-based US Kidney Research Corp., formerly Curion Research Corp., has been working on its waterless renal replacement technology since its inception in June 2015. Its latest research efforts using its novel blood purifying technology have led to the production of the first ‘synthetic urine,’ which mimics the body’s natural production and the kidney’s filtration capability.
Read More
Apple-iPhone-Watch-Series-5-11-22.png

Apple Heart Study delivers results as 3 new app-based trials begin

Nov. 22, 2019
By Stacy Lawrence
Stanford University School of Medicine and Apple Inc.have published results from the largest digital-only study. The trial has been conducted in more than 400,000 people in the U.S. over more than eight months. It was set up to screen participants via their Apple Watch for heart irregularities and then to further monitor any of those with identified issues with a wearable ECG patch.
Read More

Google's reported acquisition of Fitbit pits it against Apple Watch in health care arena

Nov. 5, 2019
By Meg Bryant

Tech giant Google LLC is taking aim at the Apple Watch with its plan to acquire wearables pioneer Fitbit Inc., of San Francisco, for $2.1 billion, or $7.35 per share, in an all-cash transaction expected to close sometime next year.


Read More

Irhythm, Verily partner to develop screening approach for asymptomatic AF

Sep. 10, 2019
By Stacy Lawrence
Previous 1 2 3 4 5 6 7 8 9 10 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Nov. 12, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Nov. 12, 2025.
  • Female doctor and patient

    Could restricting diversity efforts stall women’s health research?

    BioWorld
    Recent progress in redressing the historical underfunding and neglect of women’s health could be undermined by the backlash against diversity, equity and...
  • Man falling asleep in car

    Alkermes’ alixorexton hits endpoints in narcolepsy phase II

    BioWorld
    Alkermes plc’s placebo-controlled phase II study of alixorexton in treating narcolepsy type 2 (NT2) hit its dual primary endpoints, producing statistically...
  • Pazdur ‘optimal fit’ to lead FDA’s CDER

    BioWorld
    In reaching within to name 26-year FDA veteran Richard Pazdur as the next CDER director, FDA Commissioner Marty Makary likely chose the best possible person to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing